Members of other units:
M. Eandi, G. M. Scordo
Department of Medical Sciences-University of Uppsala-Sweden
University of Turin (ex 60%)
Carvedilol is a nonselective b-blocker that vasodilates through a1-blockade, it is effective against hypertension and can prolong the survival of patients with chronic heart failure. Carvedilol metabolism is mediated by CYP2D6, with possible contributions by CYP1A2, CYP2C9, CYP2C19 and CYP3A4. Inherited CYP2D6 polymorphisms have been shown to cause variation in carvedilol pharmacokinetics.
The objective of the project is to quantify the effects of CYP2D6 polymorphisms on carvedilol pharmacokinetics and to measure how these pharmacokinetic differences correlate with carvedilol-induced reduction of resting heart rate and with carvedilol effects on blood pressure in 24 healthy volunteers.
Pharmacogenetics, Carvedilol, Pharmacokinetics, CYP2D6